0001493152-23-037679.txt : 20231019 0001493152-23-037679.hdr.sgml : 20231019 20231019090010 ACCESSION NUMBER: 0001493152-23-037679 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231019 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231019 DATE AS OF CHANGE: 20231019 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MyMD Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001321834 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36268 FILM NUMBER: 231333498 BUSINESS ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 623 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 856-848-8698 MAIL ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 623 CITY: BALTIMORE STATE: MD ZIP: 21205 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences, Inc. DATE OF NAME CHANGE: 20170413 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences Inc DATE OF NAME CHANGE: 20050325 8-K 1 form8-k.htm
0001321834 false 0001321834 2023-10-19 2023-10-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 19, 2023

 

MyMD Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

New Jersey   001-36268   22-2983783

(State or other jurisdiction

of incorporation)

  

(Commission

File No.)

  

(IRS Employer

Identification No.)

 

MyMD Pharmaceuticals, Inc.

855 N. Wolfe Street, Suite 601

Baltimore, MD 21205

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (856) 848-8698

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, no par value per share   MYMD   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On October 19, 2023, MyMD Pharmaceuticals, Inc. (the “Company”) issued a press release announcing results from a preclinical study of its investigational cannabinoid Supera-CBD™, a novel, synthetic, non-toxic cannabidiol (CBD) analog. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
     
99.1   Press Release, dated October 19, 2023 (furnished herewith pursuant to Item 7.01).
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MYMD PHARMACEUTICALS, INC.
     
Date: October 19, 2023 By: /s/ Chris Chapman
    Chris Chapman, M.D.
    President

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced

Acute Inflammatory Pain

 

  - Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours
   
  - Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects
     
  - MyMD was issued Japanese Patent No. 7293561 B2, covering Supera-CBD as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments

 

BALTIMORE, MD – October 19, 2023 — MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced results from a preclinical study of its investigational cannabinoid Supera-CBD™, a novel, synthetic, non-toxic cannabidiol (CBD) analog. In the study, Supera-CBD targeted and quickly reduced inflammatory pain within 60 minutes, providing pain relief for up to five hours. Comparatively, traditional CBD had no effect on this type of pain in the same study.

 

“These preclinical results illustrate the potential of Supera-CBD to alleviate acute inflammatory pain related to injuries, burns, surgery, and flare-ups from chronic inflammatory conditions such as diabetic neuropathy and shingles,” said Chris Chapman, MD, president, director and chief medical officer, MyMD. “Moreover, these are exciting findings in that the effect demonstrated appears to be targeted, as Supera-CBD alleviated pain due to heat but did not affect pain related to touch in the model of inflammation. This may indicate the potential for fewer side effects compared to traditional opioid pain treatments, without the functional impairment due to numbness in affected areas.”

 

According to study researchers at a major academic center where the study was conducted, the results indicate that Supera-CBD may have an effect on the body’s TRPV1 pain system channels, which control heat-related pain.1 Added Dr. Chapman, “By targeting the TRPV1 channels, which these results indicate Supera-CBD may be capable of, we have the potential to advance treatment in inflammatory-related pain, an area of great patient need.”

 

Dr. Chapman also noted that it was very significant that the “U.S. Department of Justice Drug Enforcement Administration (DEA)’s scientific review concluded Supera-CBD will not be considered a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations or require scheduling during development.”

 

Acute pain related to inflammation, burns, and nerve-related pain affects countless individuals worldwide. The global market for pain management was valued at around $36 billion in 2021, and is expected to reach $52 billion by 2026.

 

About Supera-CBD

 

Supera-CBD™ is a synthetic, non-toxic cannabidiol (CBD) analog that is an 8000-times more potent CB2 agonist than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown in preclinical studies to have anti-inflammatory effects. Supera-CBD is a unique synthetic analog of CBD whose structure has been modified to be CB2-receptor selective. Studies to investigate Supera-CBD’s binding and affinity to CB1 and CB2 receptors show that the compound had very low affinity to CB1 and had a four-fold increase in binding to the CB2 receptor in comparison to CBD. Supera-CBD has completed genotoxicity studies and the company has initiated preclinical pain studies in partnership with Johns Hopkins Medicine.

 

On June 20, 2023, MyMD was issued Japanese Patent No. 7293561 B2, covering Supera-CBD™ as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments. With this latest issuance, the Company now has 23 issued patents worldwide protecting this drug product candidate, along with two pending applications.

 

 
 

 

About MyMD Pharmaceuticals

 

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. MyMD’s lead clinical candidate, MYMD-1®, is an orally available next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated. MYMD-1®, with its small molecule design, improved safety profile and ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-α inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases. The company has completed Phase 2 studies of MYMD-1® for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications.

 

MyMD’s second therapeutic candidate is Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times more potent a CB2 agonist (activator) than plant-based CBD.. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown to have anti-inflammatory effects. For more information, visit www.mymd.com.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance, or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the COVID-19 pandemic or similar public health emergencies on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed by MyMD on March 31, 2023, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Contact:

 

Robert Schatz

(646) 421-9523

rschatz@mymd.com

 

Media Contact:

 

Andrea Cohen

Sam Brown, Inc.
(917) 209 7163

andreacohen@sambrown.com

 

1 Reference: TRPV1 is a non-selective cation channel; when it is activated by capsaicin, sodium and calcium ions flowing through TRPV1 into the cell to depolarize nociceptive neurons, leading to action potential firing and finally the sensation of spiciness (Caterina et al., 1997).

 

 

 EX-101.SCH 3 mymd-20231019.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mymd-20231019_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mymd-20231019_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 19, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 19, 2023
Entity File Number 001-36268
Entity Registrant Name MyMD Pharmaceuticals, Inc.
Entity Central Index Key 0001321834
Entity Tax Identification Number 22-2983783
Entity Incorporation, State or Country Code NJ
Entity Address, Address Line One MyMD Pharmaceuticals, Inc.
Entity Address, Address Line Two 855 N. Wolfe Street
Entity Address, Address Line Three Suite 601
Entity Address, City or Town Baltimore
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21205
City Area Code (856)
Local Phone Number 848-8698
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, no par value per share
Trading Symbol MYMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001321834 2023-10-19 2023-10-19 iso4217:USD shares iso4217:USD shares 0001321834 false 8-K 2023-10-19 MyMD Pharmaceuticals, Inc. NJ 001-36268 22-2983783 MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street Suite 601 Baltimore MD 21205 (856) 848-8698 false false false false Common stock, no par value per share MYMD NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ M "(" / " 8$0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M " $2%-7)!Z;HJT #X 0 &@ @ 'A$0 >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " $2%-799!YDAD! #/ M P $P @ '&$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" 0% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mymd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mymd-20231019.xsd mymd-20231019_lab.xml mymd-20231019_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "mymd", "nsuri": "http://mymd.com/20231019", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mymd-20231019.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mymd-20231019_lab.xml" ] }, "presentationLink": { "local": [ "mymd-20231019_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://mymd.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-23-037679-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-037679-xbrl.zip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end